Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Core Insights - Sonnet BioTherapeutics Holdings, Inc. presented data at the 2025 AACR:IO Conference, showcasing its Fully Human Albumin Binding (FHAB®) platform for targeted immunotherapy [2][3] - The FHAB platform enhances tumor targeting and retention, potentially improving the efficacy of immunotherapeutic drugs [4][5] Company Overview - Sonnet is a clinical-stage biotechnology company focused on developing targeted immunotherapeutic drugs using its proprietary FHAB platform [9][10] - The lead program, SON-1010, is designed to treat advanced solid tumors and is currently in a Phase 1/2a study in combination with atezolizumab for platinum-resistant ovarian cancer [10] Technology and Mechanism - The FHAB platform links cytokines to a fully human albumin-binding domain, allowing for prolonged half-life and improved pharmacokinetics [4][6] - SON-1010, a recombinant human interleukin-12 (rhIL-12), is engineered to enhance immune responses by targeting the tumor microenvironment [8][10] Clinical Development - Ongoing studies include SON-1010 monotherapy, co-administration with checkpoint inhibitors, and alternating with chemotherapy to enhance therapeutic effects [6][7] - In December 2024, clinical benefit was reported in 48% of patients treated with SON-1010 at the highest dose [6] Future Prospects - The company plans to announce additional data from ongoing studies in 2025, indicating a commitment to advancing its clinical programs [5][6] - SON-1210, another candidate in development, aims to combine IL-12 with IL-15 for enhanced efficacy in treating solid tumors [10]